We are celebrating the completion of major works to reconstruct and modernize Furnace N°2 and its production lines at our Sucy-en-Brie plant in France, as part of the transformative Sucy Pharma 2025 project. The strategic development project for the Sucy-en-Brie plant began in December 2020, with a groundbreaking Capex investment of 25 million euros –
SGD Pharma’s second largest since the construction of the Saint-Quentin-Lamotte (SQLM) plant in 2016 – allowing us to cement our leading position in pharmaceutical molded glass packaging.
23.03.2021, SGD Pharma
News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.